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ABSTRACT
The in-vitro and in-vivo efﬁcacy against Candida
albicans and Candida krusei of devices impregnated
with chlorhexidine and chloroxylenol was exam-
ined. The impregnated devices produced large
zones of inhibition against both organisms (mean
size, 39 mm and 38 mm, respectively). In a rabbit
model in which segments of silicone catheters
were placed percutaneously, non-impregnated
devices were twice as likely as impregnated
devices to become colonised with either C. albi-
cans or C. krusei. Impregnated devices also had
signiﬁcantly lower colony counts of C. albicans (58
vs. 1361 CFU; p 0.008) and C. krusei (19 vs.
764 CFU; p 0.008).
Keywords Candida albicans, Candida krusei, chlorhexi-
dine, chloroxylenol, impregnated devices, rabbit model
Original Submission: 18 May 2005; Revised Submis-
sion: 23 August 2005; Accepted: 21 September 2005
Clin Microbiol Infect 2006; 12: 397–399
10.1111/j.1469-0691.2006.01369.x
Candida spp. are recognised increasingly as import-
ant causes of infection associated with medical
devices [1]. Recent surveillance data from 49
hospitals indicated that Candida spp. cause 9% of
hospital-acquired bloodstream infections [2].
Candida infections associated with medical
devices tend to be more problematic than bacterial
infections. Thus,Candida continues to be associated
with the highest crude mortality rate (39–40%)
resulting from hospital-acquired bloodstream
infections [2,3].
The serious medical complications, difﬁcult
management and high economic burden of
Candida device-associated infections prompted
an exploration of the potential preventive efﬁcacy
of innovative approaches [4]. Since device coloni-
sation can be a prelude to clinical infection [5], it
is possible that devices impregnated with agents
that possess antifungal activity may be clinically
protective. The objective of the present study was
to investigate the in-vitro and in-vivo efﬁcacy of
devices impregnated with the antiseptic combi-
nation of chlorhexidine and chloroxylenol against
Candida albicans (the most common Candida sp.)
and Candida krusei (the most inherently azole-
resistant Candida sp.).
Eighteen French silicone catheters (Cook Inc.,
Bloomington, IN, USA) were impregnated by
dipping in a solution of chlorhexidine (50 mg ⁄mL)
and chloroxylenol (50 mg ⁄mL), followed by
drying overnight and rinsing with deionised
water. Segments (2 cm) of both impregnated and
control catheters were sterilised with ethylene
oxide gas before testing. Mean quantities of
102 lg of chlorhexidine and 156 lg of chloroxyle-
nol were extracted from 2-cm segments of the
gas-sterilised impregnated catheters.
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The antimicrobial activity of chlorhexi-
dine ⁄ chloroxylenol-impregnated devices was
assessed in vitro by a modiﬁed Kirby–Bauer
technique [6]. The antimicrobial activity of non-
impregnated catheters was also examined. Zones
of inhibition were determined, in triplicate,
against one clinical isolate of C. albicans and one
of C. krusei, each of which had caused a vascular
catheter-associated bloodstream infection.
The animal protocol was approved by the
Institutional Research Committee. After induction
of anaesthesia, eight New Zealand white, speciﬁc
pathogen-free, female rabbits (body mass, 3–5 kg)
received an intramuscular injection of cefazolin
(80 mg ⁄kg) to help prevent infection by skin
bacteria. Their backs were shaved, cleansed with
chlorhexidine gluconate followed by povidone-
iodine, and then draped in a sterile fashion. Two
1-cm transverse incisions were made in each
rabbit, 8 cm apart, on each side of the vertebrae,
and four 2-cm devices (two impregnated devices
and two control devices) were inserted percuta-
neously, allowing a 1-cm segment to remain
outside the body. A 0.1-mL aliquot of C. albicans
equivalent to 104 CFU (an inoculum found
previously to cause device colonisation in most
instances) was placed via a syringe at the
catheter–dermal junction in four rabbits. The
other four rabbits were inoculated with 104 CFU
of C. krusei. Therefore, in total, 16 devices impreg-
nated with antimicrobial agents (eight inoculated
with C. albicans and eight inoculated with C. kru-
sei) and 16 control devices (eight inoculated with
C. albicans and eight inoculated with C. krusei)
were placed in eight rabbits. The inserted devices
were secured in place using 4-0 Vicryl suture. The
outer end of each catheter segment was sealed
with 4-0 Vicryl suture to prevent intraluminal
entry of organisms into the subcutaneous area. All
wounds were covered by Ioban antimicrobial
incise drapes (3M, Minneapolis, MN, USA), and
a dressing was applied.
The rabbits were killed humanely 1 week after
surgery and the catheters were explanted. The
internalised 1-cm segment was placed in 1 mL of
saline, sonicated for 5 min, and then vortexed for
30 s. After serial dilution on to blood agar plates
and incubation at 37C for 72 h, Candida colony
counts were determined. Device colonisation was
deﬁned as isolation of Candida (detection limit,
10 CFU) from these sonication cultures.
The proportions of the two groups of devices
that became colonised with Candida were com-
pared using the McNemar test, and the Candida
CFU counts from the two groups of devices were
compared by the Wilcoxon signed-rank test, with
p £ 0.05 considered to indicate a signiﬁcant
difference.
The mean zones of inhibition around the
impregnated devices were 39 mm (range, 37–
41 mm) for C. albicans and 38 mm (range, 36–
40 mm) for C. krusei. No zones of inhibition were
detected around the non-impregnated devices.
No rabbits exhibited evidence of sepsis or
failure to thrive, and no drainage was noted
around the exit sites. All implanted devices were
cultured post mortem and included in the analysis.
As shown in Table 1, half of the impregnated
devices became colonised with C. albicans or
C. krusei, but the differences compared with the
control devices were not statistically signiﬁcant
because of the small number of implanted
devices. Signiﬁcantly lower colony counts of
C. albicans (p 0.008) and C. krusei (p 0.008) were
obtained from the impregnated devices.
Although antiseptic-impregnated [7] and anti-
biotic-impregnated [8,9] central venous catheters
that have been demonstrated to protect against
catheter-related bloodstream infection have also
been shown to display broad-spectrum in-vitro
activity against both bacteria and Candida, the
efﬁcacy of such impregnated devices in prevent-
ing colonisation by Candida in an animal model
has not been reported previously. The results of
the present study indicate that devices impregna-
ted with chlorhexidine and chloroxylenol can
reduce colonisation by both C. albicans and
C. krusei compared with control devices. Preven-
tion of Candida infections of medical devices is
particularly important, since cure of such infec-
tions invariably requires removal of the infected
device [7,10–13].
Table 1. Comparison of Candida colonisation of antimicro-
bial-impregnated vs. control devices
Type of device
No. of devices colonised
with Candida (%)
Mean no. of
colonies ± SE
C. albicans C. krusei C. albicans C. krusei
Impregnated 4 ⁄ 8 (50%) 4 ⁄ 8 (50%) 58 ± 37 19 ± 13
Control 8 ⁄ 8 (100%) 8 ⁄ 8 (100%) 1361 ± 484 764 ± 188
SE, standard error.
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The production of large zones of inhibition
around impregnated devices reﬂects the degree of
antimicrobial activity of the coating agents that
leach from the surface of the catheter. This serves
to inhibit the adherence of organisms, not only to
the surface of the device, but also within the
surrounding bioﬁlm layer. Although not tested
speciﬁcally for Candida, an in-vitro zone of inhi-
bition of 10–15 mm against Staphylococcus aureus
correlates well with in-vivo efﬁcacy [14]. When
incorporated on to the surface of titanium cylin-
ders, the combination of chlorhexidine and chlo-
roxylenol has been shown in vitro to produce
large zones of inhibition against bacteria (inclu-
ding S. aureus, Staphylococcus epidermidis, Pseudo-
monas aeruginosa and Escherichia coli) and
C. albicans [15]. In rabbits with fractured tibias,
placement of intramedullary nails coated with
chlorhexidine and chloroxylenol also protected
against S. aureus infection when compared with
uncoated nails [16].
These promising results invite further explo-
ration of the potential to use chlorhexidine and
chloroxylenol for impregnating medical devices.
Although both agents have been used safely in
humans (chlorhexidine in impregnated central
venous catheters and in topical applications;
chloroxylenol in topical applications), the toxic-
ity of chlorhexidine ⁄ chloroxylenol-impregnated
devices must be assessed in vitro and in vivo
before potential clinical applications are consid-
ered.
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